【摘要】：隨著中國社會主義市場經(jīng)濟(jì)的不斷發(fā)展,人們越來越關(guān)注健康和個人的健康生活,藥物的安全性顯得尤為重要,關(guān)系到人民的身體健康安全、社會和經(jīng)濟(jì)生活。而隨著日常保健的需要和回歸自然的號召,為中國傳統(tǒng)醫(yī)藥產(chǎn)業(yè)的發(fā)展提供了廣闊的空間,而中國醫(yī)藥行業(yè)未來的生存和發(fā)展,成為大家關(guān)注的焦點(diǎn)。 PL藥業(yè)公司成立于1998年,公司的主營業(yè)務(wù)：研究生產(chǎn)中藥配方顆粒,中成藥和靈芝,烏發(fā)濃等其他保健食品。目前共開發(fā)了150多個復(fù)方和600多個單方品種。 主要使用于國內(nèi)各省市的中醫(yī)醫(yī)院和綜合性醫(yī)院以及香港澳門醫(yī)院,其中,國內(nèi)已有超過300家醫(yī)院在使用我公司的產(chǎn)品。公司的產(chǎn)品出口到香港、澳門、新加坡、美國等國家和地區(qū)。 本論文中,以發(fā)展戰(zhàn)略理論為基礎(chǔ),結(jié)合中國的醫(yī)藥行業(yè)外部環(huán)境的現(xiàn)狀,得出外部因素分析矩陣,以幫助企業(yè)分析,總結(jié)和評估政治、經(jīng)濟(jì)、市場及競爭對手等信息。找出對企業(yè)影響最重要的因素。然后從PL藥業(yè)公司內(nèi)部環(huán)境：生產(chǎn)運(yùn)作管理、信息化建設(shè)情況、技術(shù)與科研狀況、業(yè)務(wù)模式、人力資源和營銷模式分析和研究,做出內(nèi)部因素評價矩陣,分析企業(yè)在該行業(yè)中的地位。根據(jù)之前的分析結(jié)果,再對企業(yè)進(jìn)行了SWOT分析,得出適合企業(yè)的備選戰(zhàn)略,運(yùn)用QSPM分析法找出企業(yè)發(fā)展的總體戰(zhàn)略,即后向一體化增長型戰(zhàn)略、競爭戰(zhàn)略—成本領(lǐng)先戰(zhàn)略。最后,在運(yùn)營管理、價值鏈、人力資源、知識產(chǎn)權(quán)貿(mào)易、企業(yè)信息化、產(chǎn)品優(yōu)化、國際貿(mào)易等方面提出了具體的發(fā)展戰(zhàn)略實(shí)施途徑和方法,并且對類似的中藥制藥企業(yè)發(fā)展戰(zhàn)略管理具有一定的參考意義。
[Abstract]:With the continuous development of China's socialist market economy, people pay more and more attention to health and personal healthy life. The safety of drugs is particularly important, which is related to the health and safety of the people, social and economic life. With the need of daily health care and the call to return to nature, the development of Chinese traditional medicine industry has provided a broad space, and the future survival and development of Chinese medicine industry has become the focus of attention. PL Pharmaceutical Co., Ltd. was founded in 1998, the company's main business: research and production of traditional Chinese medicine formula granules, proprietary Chinese medicine and Ganoderma lucidum, Wufa thick and other health food. At present, a total of more than 150 compound and more than 600 unilateral varieties. It is mainly used in Chinese medicine hospitals and general hospitals in various provinces and cities in China and hospitals in Hong Kong and Macao. Among them, more than 300 hospitals in China are using our products. The company's products are exported to Hong Kong, Macao, Singapore, the United States and other countries and regions. In this paper, based on the development strategy theory and the current situation of the external environment of Chinese pharmaceutical industry, the external factor analysis matrix is obtained to help enterprises analyze, summarize and evaluate the information of politics, economy, market and competitors. Identify the most important factors affecting the business. Then from the PL pharmaceutical company internal environment: production and operation management, information construction, technology and scientific research status, business model, human resources and marketing model analysis and research, to make internal factor evaluation matrix, Analyze the position of the enterprise in the industry. According to the previous analysis results, the SWOT analysis of the enterprise is carried out, and the alternative strategy suitable for the enterprise is obtained, and the overall strategy of the enterprise development is found by using the QSPM analysis method, that is, the backward integrated growth strategy, the competitive strategy and the cost leading strategy. Finally, in the aspects of operation management, value chain, human resources, intellectual property trade, enterprise informatization, product optimization, international trade and so on, the paper puts forward the specific ways and methods to implement the development strategy. And it has certain reference significance to the development strategy management of the similar traditional Chinese medicine pharmaceutical enterprises.
【學(xué)位授予單位】：廣西大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2014
【分類號】：F272;F426.72

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 應(yīng)維華;;經(jīng)濟(jì)全球化背景下中國中藥企業(yè)的戰(zhàn)略選擇[J];浙江中醫(yī)學(xué)院學(xué)報;2005年06期

2 周靜;林江;;淺談中藥企業(yè)的現(xiàn)代化國際化發(fā)展策略[J];廣西中醫(yī)學(xué)院學(xué)報;2008年01期

3 李泊溪;;中藥現(xiàn)代化產(chǎn)業(yè)推進(jìn)戰(zhàn)略[J];經(jīng)濟(jì)管理;2001年21期

4 汪啟航;廖鳳霞;盧曉萍;;基于SWOT框架的中藥企業(yè)專利戰(zhàn)略分析[J];科技管理研究;2009年01期

5 王冬;張建生;;我國中藥企業(yè)面臨的挑戰(zhàn)和對策[J];內(nèi)蒙古中醫(yī)藥;2008年08期

6 吳海燕;饒惠霞;張立鎮(zhèn);;勝任力模型在我國中藥企業(yè)管理現(xiàn)代化中的應(yīng)用分析[J];企業(yè)經(jīng)濟(jì);2009年04期

7 張李眺;;論企業(yè)發(fā)展戰(zhàn)略[J];商場現(xiàn)代化;2006年15期

8 宇文亞;韓學(xué)杰;王麗穎;史楠楠;王永炎;呂愛平;;對中醫(yī)藥標(biāo)準(zhǔn)化發(fā)展戰(zhàn)略制訂方法的思考[J];中西醫(yī)結(jié)合學(xué)報;2011年05期

9 王廣平;張競之;;基于知識傳播途徑的中藥產(chǎn)業(yè)國際化發(fā)展問題探討[J];中國現(xiàn)代中藥;2009年03期

10 陳昊群;郭志成;劉蘭茹;;我國中藥企業(yè)知識產(chǎn)權(quán)戰(zhàn)略研究[J];中國藥業(yè);2011年08期

，

本文編號：2359562